SIBO INFO Blog

Research on the new mBiota Elemental Diet is discussed.

Effectiveness of the Elemental Diet for Different Gases

• Hydrogen Gas: The new elemental diet demonstrated a high success rate, normalizing hydrogen breath tests for almost every patient. This outcome is noted as being even better than what was observed in the Vivonex study from 2003.
• Methane Gas: It also showed effectiveness for methane, with approximately 70-80% of patients experiencing positive results. This is also considered an improvement compared to findings from the Vivonex study.

Importance of Taste and Patient Compliance

• A critical factor for the success of an elemental diet is its taste and the patient's ability to comply with the regimen.
• The new elemental diet discussed in the video is reported to have good taste, even by individuals who are sensitive tasters.
• Compliance is essential; if a patient cannot tolerate the diet, the investment is lost, and the treatment is ineffective. Feedback from doctors indicates that their patients find this diet tastes better than other elemental diets.

Findings on Hydrogen Sulfide Gas

• While full details are not yet publicly disclosed, Dr. Pimentel mentions ongoing research.
• Dr. Siebecker's dedicated study group, focusing on hydrogen sulfide for three years, found elemental diets  to be successful for hydrogen sulfide gas.

Products mentioned (affiliate link)
– mBiota Elemental Diet - $25 Off with code SIBO

This video delves into the complexities and challenges of diagnosing Small Intestinal Bacterial Overgrowth (SIBO) in individuals taking popular GLP-1/GIP medications like semaglutide and tirzepatide.
Key Discussion Points

• Breath Tests:
  • GLP-1 drugs are known to slow down the digestive system.
  • This slowed transit means that the lactulose or glucose used in breath tests may not move out of the stomach as expected.
  • Consequently, a breath test might show a "flat line," not because SIBO is absent, or there is hydrogen sulfide, but because the substrate is not reaching the small intestine for bacterial fermentation. 
• Aspiration Studies (Endoscopy):
  • Similarly, these medications cause the stomach to empty more slowly, meaning food remains in the stomach longer.
  • This hinders the ability to perform accurate aspiration studies, as food can contaminate the catheter used to collect samples, leading to unreliable results.
• Treatment Efficacy:
  • The slow gastric emptying also raises questions about the effectiveness of treatments like rifaximin when administered to patients on GLP-1/GIP drugs. It's unclear if the antibiotic will successfully leave the stomach or be properly absorbed in the small intestine, to treat SIBO.

Potential Approaches and Unanswered Questions

• Testing Timing: One colleague suggested testing on the morning before taking a dose, or basically, one week after starting the medication, since they are dosed once a week.
• Drug Discontinuation: Another idea proposed is to stop the GLP-1/GIP medication for one to two weeks before undergoing a SIBO test.
• Limited Evidence: While stopping for a minimum of one week is sometimes recommended for SIBO breath tests, there hasn't been enough systematic observation to confirm its effectiveness.

Conclusion
Diagnosing and treating SIBO in patients using GLP-1/GIP drugs presents significant question marks. The impact of these medications on gut function creates a complex scenario where standard diagnostic tools are unreliable.

Products mentioned
– GLP-1 medicines are Ozempic and Wegovy (Semaglutide)
– GLP-1 + GIP medicines are Mounjaro and Zepbound (Tirzepatide)

This video addresses a common concern: are there treatments to do if you experience food poisoning to help prevent getting SIBO (Small Intestinal Bacterial Overgrowth) afterwards.

Steroids

• A single study conducted by a Canadian group from McMaster University investigated this.
  • Participants who experienced food poisoning were given steroids shortly afterward to reduce the immune response.
  • Outcome: This intervention did not prevent the development of IBS/SIBO in the study subjects.
• Why Steroids Didn't Work: Steroids can reduce inflammation temporarily, but they do not prevent the formation of antibodies, which are believed to play a role in the auto-immune reaction leading to post-infectious IBS/SIBO.

Current Understanding and Limitations

• Post-Food Poisoning Actions: Based on current understanding, once food poisoning has occurred and the initial immune response is triggered, there are no guaranteed interventions to prevent subsequent conditions like IBS.
• Lack of Definitive Studies: While there's a strong belief that preventing food poisoning is key, and that prompt treatment of food poisoning might reduce the risk of IBS, robust studies to scientifically prove these strategies are currently lacking.
• Challenges in Research: Conducting trials to test these preventative or early treatment measures is difficult and expensive, which is why definitive answers remain elusive.

Recommended Strategies (Based on current beliefs and limited evidence)

• Prevention is Key:
  
  • The most effective approach is to prevent food poisoning from occurring in the first place, especially when traveling to areas where foodborne illnesses are more common.
    
  • Taking antibiotics as a preventative measure before traveling to high-risk areas is suggested as potentially effective.
• Prompt Treatment: If food poisoning does occur, it is believed that prompt and effective treatment may be beneficial.
  • The rationale is that a shorter duration of food poisoning may lead to a lower likelihood of developing IBS/SIBO.

Conclusion

• While the exact mechanisms and preventative treatments are still areas for further research, prioritizing food safety and seeking timely medical attention for gastrointestinal infections are recommended steps.

This video explores significant findings from recent studies on the human gut microbiome, focusing on fungal components and their implications for health and resistance.

Research on the Small Intestine Fungal (Yeast) Microbiome (Fungiome)

• The team conducted the first-ever shotgun sequencing of the small intestine, providing novel data on the fungal population.
• The study identified that approximately 5% of patients with SIBO (Small Intestinal Bacterial Overgrowth) may also have SIFO (Small Intestinal Fungal Overgrowth).
• Commonly identified fungi include Candida albicans and, occasionally, Candida glabrata, which is noted as being more toxic.
• An interesting correlation was observed: higher levels of Candida albicans were associated with higher levels of SIBO.
• The researchers emphasize that more knowledge is needed to fully interpret these findings.
• A key challenge is the absence of a standard breath test or a reliable indirect measurement for SIFO.

Fungal Production of Penicillin and its Link to Antimicrobial Resistance

• A separate, highly important study identified fungal elements within the normal gut that produce penicillin.
• This finding highlights that fungi can naturally produce penicillin, a known antibiotic.
• When these penicillin-producing fungi are present, an increase in penicillin resistance among gut bacteria was observed.
• This suggests that fungal components may play a role in antibiotic resistance, moving beyond human-induced causes.
• A leading hypothesis arising from this research is that these fungal elements might help control SIBO by producing penicillin locally, thus regulating bacterial populations.